Core Viewpoint - Warner Pharmaceuticals (688799.SH) announced that its associate company, Shanghai Zhigen Pharmaceutical Technology Co., Ltd., has completed Phase I clinical trials for ZG-002, a novel drug for autoimmune diseases, with the approval of the National Medical Products Administration [1] Group 1: Clinical Trial Details - ZG-002 is a first-in-class new drug developed by Zhigen Pharmaceutical, currently intended for the treatment of moderate to severe plaque psoriasis [1] - The primary objective of the clinical trial was to evaluate the safety, tolerability, pharmacokinetics, and food effects of ZG-002 in healthy adult subjects [1] - The trial results indicate that ZG-002 has good safety and tolerability under the current dosing regimen, with clear pharmacokinetic characteristics [1] Group 2: Future Research Implications - The clinical data obtained from this study supports the further exploration of ZG-002 in subsequent clinical research involving patient populations [1]

Core Viewpoint - Warner Pharmaceuticals announced the completion of Phase I clinical trials for ZG-002, a novel drug developed by its affiliate, Digen Pharmaceuticals, aimed at treating moderate to severe plaque psoriasis [1] Group 1: Clinical Trial Results - The clinical trial results indicate that ZG-002 has good safety and tolerability after both single and multiple doses within the explored dosage range, with no serious adverse events reported [1] - Pharmacokinetic characteristics of ZG-002 are clearly defined, showing that blood concentration and exposure levels increase with the dosage [1] - The trial results also demonstrate a decrease in IFN-γ levels with increased drug exposure, suggesting potential therapeutic efficacy of ZG-002 for moderate to severe psoriasis [1]

Core Viewpoint - Warner Pharmaceutical experienced a decline in stock price and trading volume, with significant net financing outflows on January 29, indicating potential investor caution [1]. Group 1: Financing and Trading Data - On January 29, Warner Pharmaceutical's stock fell by 0.41%, with a trading volume of 192 million yuan [1]. - The financing buy-in amount for the day was 18.32 million yuan, while the financing repayment was 42.29 million yuan, resulting in a net financing outflow of 23.97 million yuan [1]. - As of January 29, the total financing and securities lending balance for Warner Pharmaceutical was 252 million yuan, with the financing balance accounting for 3.98% of the circulating market value, which is below the 50th percentile level over the past year [1]. Group 2: Company Overview and Financial Performance - Warner Pharmaceutical, established on April 30, 2001, and listed on July 13, 2021, is located in Changsha, Hunan Province, and specializes in the research, production, and sales of chemical raw materials, chemical drug formulations, and traditional Chinese medicine formulations [1]. - The company's revenue composition includes 73.19% from formulation products, 25.22% from raw materials and intermediates, 1.52% from technical services, 0.06% from plant extracts and food, and 0.01% from other sources [1]. - For the period from January to September 2025, Warner Pharmaceutical reported a revenue of 1.086 billion yuan, reflecting a year-on-year growth of 1.55%, and a net profit attributable to shareholders of 207 million yuan, marking a year-on-year increase of 30.75% [2]. Group 3: Shareholder and Dividend Information - As of September 30, 2025, the number of shareholders for Warner Pharmaceutical was 6,416, a decrease of 11.83% from the previous period, while the average circulating shares per person increased by 13.42% to 20,467 shares [2]. - The company has distributed a total of 291 million yuan in dividends since its A-share listing, with 225 million yuan distributed over the past three years [3]. - Among the top ten circulating shareholders, Anxin Medical Health Stock A holds 1.2294 million shares, remaining unchanged from the previous period, while China Europe Enjoy Life Mixed A has entered the list as a new shareholder with 1.0891 million shares [3].

Core Viewpoint - Warner Pharmaceuticals announced significant corporate governance changes, including alterations to registered capital, cancellation of the supervisory board, adjustments to the board of directors, and amendments to the company's articles of association [1] Group 1 - The company will hold its fourth board meeting and fourth supervisory board meeting on December 10, 2025, followed by a second extraordinary shareholders' meeting on December 26, 2025, to review the proposed changes [1] - The company has completed the necessary business registration changes and the filing of the revised articles of association, receiving a new business license from the Changsha Market Supervision Administration [1]

湖南华纳大药厂股份有限公司 关于完成工商变更登记并换发营业执照的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 湖南华纳大药厂股份有限公司（以下简称"公司"）于 2025 年 12 月 10 日召 开第四届董事会第四次会议和第四届监事会第四次会议、2025 年 12 月 26 日召 开 2025 年第二次临时股东大会，审议通过了《关于变更注册资本、取消监事会、 调整董事会人数、修订<公司章程>并办理工商变更登记的议案》。具体内容详见 公司于 2025 年 12 月 11 日在上海证券交易所网站（www.sse.com.cn）披露的《湖 南华纳大药厂股份有限公司关于变更注册资本、取消监事会、调整董事会人数、 修订<公司章程>并办理工商变更登记及修订、制定公司部分治理制度的公告》 （公告编号：2025-090）。 近日，公司已完成上述事项的工商变更登记及变更后《公司章程》的备案手 续，并取得了长沙市市场监督管理局换发的《营业执照》，变更后的具体登记事 项如下： 名称：湖南华纳大药厂股份有限公司 证券代码：688799 证 ...

Core Viewpoint - Warner Pharmaceuticals has voluntarily withdrawn its drug registration application for Lidocaine Gel Patch, which is primarily used for alleviating postherpetic neuralgia, indicating a strategic decision based on research and development considerations [1] Group 1: Company Actions - The company received a termination notice from the National Medical Products Administration regarding the drug registration application for Lidocaine Gel Patch [1] - Warner Pharmaceuticals submitted the application for market approval in March 2025, which was accepted by the regulatory authority [1] - The decision to withdraw the application will not have a significant impact on the company's current or future operations and performance [1]

公司于 2025 年 3 月向国家药品监督管理局递交该产品的上市许可申请并获 得受理。经审慎研究，结合研发策略，公司决定主动撤回本次药品注册申请。 该药品注册申请的主动撤回并终止不会对公司当期及未来生产经营与业绩 产生重大影响。敬请广大投资者注意投资风险。 特此公告。 公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 近日，湖南华纳大药厂股份有限公司（以下简称"公司"）收到国家药品监 督管理局核准签发的《药品注册申请终止通知书》，同意公司撤回利多卡因凝胶 贴膏的注册申请。现将相关情况公告如下： | 药品名称 | 注册分类 | 受理号 | 通知书编号 | 审批结论 | | --- | --- | --- | --- | --- | | | | CYHS2501139 | 2026L00051 | 根据《药品注册管理办法》第八十九条以 及申请人的撤回申请《关于撤回利多卡因 凝胶贴膏药品注册上市许可申请的请示报 | | 利多卡因 | 化学药品 | | | | | 凝胶贴膏 | 4 类 | | | | | | | | | 告》，同意本 ...

Core Viewpoint - Warner Pharmaceuticals (688799.SH) has voluntarily withdrawn its drug registration application for Lidocaine Gel Patch, which is primarily used for alleviating postherpetic neuralgia without broken skin, as per the approval from the National Medical Products Administration [1] Group 1 - The company received a termination notice for the drug registration application from the National Medical Products Administration [1] - The application for the Lidocaine Gel Patch was submitted in March 2025 and was accepted, but the company decided to withdraw it after careful consideration of its R&D strategy [1] - The withdrawal of the drug registration application will not have a significant impact on the company's current and future operations and performance [1]

Group 1 - The core viewpoint of the news is that the A-share market is seeing a strong performance in innovative drug concept stocks, driven by a policy encouraging the sale of innovative drugs and reference preparations in retail pharmacies [1] Group 2 - Guangshentang (300436) experienced a 20% increase, with a total market value of 15.3 billion and a year-to-date increase of 8% [2] - Zhongsan Co. (301093) rose by 12%, with a market capitalization of 13.8 billion and a year-to-date increase of 63.89% [2] - Hanshang Group (600774) saw a 10% increase, with a market value of 3.408 billion and a year-to-date increase of 26.37% [2] - Hite Bio (300683) increased by 7.92%, with a market capitalization of 4.371 billion and a year-to-date increase of 20.41% [2] - Bibete (688759) rose by 6.64%, with a market value of 24.9 billion and a year-to-date increase of 90.09% [2] - Shutaishen (300204) increased by 5.78%, with a market capitalization of 13.6 billion and a year-to-date increase of 4.58% [2] - Chengdu Xian Dao (688222) rose by 5.42%, with a market value of 13.8 billion and a year-to-date increase of 46.78% [2] - Haiwang Bio (000078) increased by 5.23%, with a market capitalization of 10.1 billion and a year-to-date increase of 10.40% [2] - Jiuzhoutong (600998) rose by 4.71%, with a market value of 28 billion and a year-to-date increase of 8.59% [2] - Hongbo Pharmaceutical (301230) increased by 4.60%, with a market capitalization of 6.76 billion and a year-to-date increase of 62.48% [2] - Huana Pharmaceutical (688799) rose by 4.09%, with a market value of 6.882 billion and a year-to-date increase of 9.87% [2]

Group 1 - Warner Pharmaceutical's stock increased by 5.52%, reaching 49.88 CNY per share, with a trading volume of 177 million CNY and a turnover rate of 2.77%, resulting in a total market capitalization of 6.55 billion CNY [1] - The company, established on April 30, 2001, and listed on July 13, 2021, is located in Changsha, Hunan Province, and specializes in the research, production, and sales of chemical raw materials, chemical drug formulations, and traditional Chinese medicine formulations [1] - The revenue composition of the company includes 73.19% from formulation products, 25.22% from raw materials and intermediates, 1.52% from technical services, 0.06% from plant extracts and food, and 0.01% from other sources [1] Group 2 - Anxin Fund's Anxin Medical Health Stock A (010709) holds 1.2294 million shares of Warner Pharmaceutical, unchanged from the previous period, representing 0.94% of the circulating shares, with an estimated floating profit of approximately 3.2088 million CNY [2] - The fund, established on January 12, 2021, has a current scale of 362 million CNY, with a year-to-date return of 10.02%, ranking 1184 out of 5542 in its category, and a one-year return of 74.07%, ranking 305 out of 4256 [2] - The fund manager, Chi Chenshen, has been in position for 5 years and 12 days, managing a total asset scale of 1.691 billion CNY, with the best fund return during his tenure at 57.47% and the worst at 53.57% [3] Group 3 - Anxin Medical Health Stock A (010709) has Warner Pharmaceutical as its eighth largest holding, with 1.2294 million shares, unchanged from the previous period, accounting for 3.47% of the fund's net value, and an estimated floating profit of approximately 3.2088 million CNY [4]